VCEL
Vericel Corp
$47.00
-1.31 (-2.71%)
At close · Jul 10
Market Cap
$2.40B
Shares
51,068,228
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$276.26M
+16.5%
FY2025
Net Income
$16.52M
+59.4%
FY2025
Gross Margin
74.42%
+1.9pp
FY2025
Operating Margin
4%
+2.1pp
FY2025
Diluted EPS
$0.32
+60%
FY2025
Operating Cash Flow
$51.91M
-10.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $326M – $336M | $292.09M | $276.26M | $237.22M | $197.52M | $164.37M | $156.18M | $124.18M | $117.85M | $90.86M | $63.92M | $54.38M | $51.17M | $28.8M | $19K | $21K | $18K | |
| — | $73.49M | $70.66M | $65.12M | $61.94M | $54.58M | $50.16M | $39.95M | $37.57M | $32.16M | $30.35M | $28.31M | $26.47M | $17.29M | $4000 | $6000 | $4000 | |
| — | $218.59M | $205.6M | $172.11M | $135.58M | $109.79M | $106.03M | $84.23M | $80.28M | $58.7M | $33.57M | $26.08M | $24.7M | $11.5M | $15K | $15K | — | |
| — | — | 74.42% | 72.55% | 68.64% | 66.8% | 67.88% | 67.83% | 68.12% | 64.6% | 52.52% | 47.95% | 48.27% | 39.95% | 78.95% | 71.43% | — | |
| — | $28.41M | $27.56M | $24.8M | $21.04M | $19.94M | $16.29M | $13.02M | $30.39M | $13.6M | $12.94M | $15.3M | $18.89M | $21.26M | $15.1M | $26.03M | $21.33M | |
| — | $93.95M | $90.2M | $82.14M | $69.01M | $60.93M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $80.47M | $76.79M | $60.65M | $51.99M | $45.98M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $174.41M | $166.99M | $142.79M | $121M | $106.9M | $97.59M | $68.84M | $61.14M | $49.01M | $35.61M | $27.39M | $22.48M | $13.77M | $5.88M | $7.75M | $7.72M | |
| — | — | — | — | — | — | — | — | — | — | — | $300K | $300K | $200K | $0 | — | — | |
| — | — | $11.54M | $5.5M | $4.63M | $3.98M | $2.97M | $2.38M | $1.7M | $1.43M | $1.61M | $1.89M | $1.59M | $752K | $489K | $649K | $647K | |
| — | — | — | — | — | — | — | — | — | — | — | $100K | — | $3M | $408K | — | — | |
| — | $202.82M | $194.56M | $167.59M | $142.04M | $126.85M | $113.88M | $81.86M | $91.53M | $62.61M | $48.55M | $45.32M | $41.37M | $35.04M | $20.98M | $33.78M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $333.36M | $33.78M | $29.06M | |
| — | $15.77M | $11.04M | $4.52M | -$6.46M | -$17.06M | -$7.85M | $2.37M | -$11.25M | -$3.91M | -$14.98M | -$19.25M | -$16.67M | -$23.53M | -$20.96M | -$33.76M | -$29.04M | |
| — | — | 4% | 1.9% | -3.27% | -10.38% | -5.03% | 1.91% | -9.55% | -4.3% | -23.44% | -35.39% | -32.58% | -81.73% | -110336.84% | -160761.9% | -161333.33% | |
| — | — | $22.59M | $10.02M | -$1.83M | -$13.08M | -$4.89M | $4.76M | -$9.55M | -$2.48M | -$13.37M | -$17.36M | -$15.08M | -$22.78M | -$20.48M | -$33.11M | -$28.39M | |
| — | $637K | $630K | $614K | $600K | $366K | $4000 | $6000 | $8000 | $31K | $92K | $15K | $9000 | $6000 | $11K | $12K | $10K | |
| — | $7.2M | $7.01M | $6.41M | $4.63M | $1.34M | $224K | $691K | $1.61M | $897K | $14K | $8000 | $36K | $24K | $16K | $50K | $53K | |
| — | $6.55M | $6.33M | $5.99M | $4.1M | $1.07M | $272K | $672K | $1.59M | -$4.23M | -$2.3M | -$321K | $331K | $3.61M | $5.34M | $4.29M | $9.37M | |
| — | — | $17.38M | $10.51M | -$2.37M | -$15.99M | -$7.58M | $3.04M | -$9.67M | -$8.14M | -$17.29M | -$19.57M | -$16.34M | -$19.92M | -$15.62M | -$29.47M | -$19.67M | |
| — | — | $859K | $148K | $814K | $721K | -$111K | $180K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | |
| — | $21.46M | $16.52M | $10.36M | -$3.18M | -$16.71M | -$7.47M | $2.86M | -$9.67M | -$8.14M | -$17.29M | -$19.57M | -$16.34M | -$19.92M | -$15.62M | -$29.47M | -$19.67M | |
| — | — | 5.98% | 4.37% | -1.61% | -10.17% | -4.78% | 2.31% | -8.2% | -8.96% | -27.04% | -35.98% | -31.93% | -69.18% | -82221.05% | -140352.38% | -109266.67% | |
| — | — | — | — | — | — | — | — | — | -$8.14M | -$17.29M | -$27.15M | -$23.08M | -$25.93M | -$20.97M | -$33.47M | -$19.67M | |
| — | $21.16M | $16.79M | $10.47M | -$2.3M | -$17.53M | -$7.64M | $2.86M | -$9.61M | -$8.18M | -$17.29M | -$19.57M | -$16.27M | -$19.99M | -$15.62M | -$29.47M | — | |
| USD/shares | — | — | $0.33 | $0.21 | -$0.07 | -$0.35 | -$0.16 | $0.06 | -$0.22 | -$0.20 | — | — | — | — | — | — | — |
| USD/shares | — | — | $0.32 | $0.20 | -$0.07 | -$0.35 | -$0.16 | $0.06 | -$0.22 | -$0.20 | — | — | — | — | — | — | — |
| shares | — | — | 50.34M | 48.85M | 47.59M | 47.13M | 46.47M | 45.22M | 44.18M | 40.24M | 33.36M | 23.09M | 23.76M | 11.64M | 3.02M | 2.06M | 38.63M |
| shares | — | — | 52.15M | 51.68M | 47.59M | 47.13M | 46.47M | 47.28M | 44.18M | 40.24M | 33.36M | 23.09M | 23.76M | 11.64M | 3.02M | 2.06M | 38.63M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
109.30×
Biotechnology median 7.52×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| MACI Implants and Kits | $239,506,000 | $197,309,000 | $164,800,000 | $131,967,000 | $111,554,000 | $94,432,000 | $91,620,000 | — |
| Other Revenue | — | — | — | — | — | — | $0 | $0 |
Key facts
CIK
887359
CUSIP
92346J108
13F (30d)
12 filings
12 filers
Visit website
Investor relations